As a great protein machine, ubiquitin-proteasome has become an important target for scientists to develop potentially effective drugs for diseases in recent decades of research.
The FDA has accepted a marketing application for Johnson & Johnson and partner Legend Biotech's BCMA-directed CAR-T therapy ciltacabtagene autoleucel (cilta-cel) for priority review as a potential treatment of adults with relapsed and/or refractory